Furthermore, homozygous deletions/mutations or epigenetic silencing of cyclin-dependent kinase inhibitor 2A (CDKN2A) have been shown to contribute to the loss of function of this tumor suppressor gene in HCC [7, 9, 15, 16]. The gene discussed is CDKN2A; the disease is hepatocellular carcinoma.